Viveve Medical Inc (VIVE, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Viveve Medical Inc is a women's sexual health company focused on the commercialization of a non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. Viveve Medical Inc has a market cap of $41.500 million; its shares were traded at around $0.92 with and P/S ratio of 1.27.
For the last quarter Viveve Medical Inc reported a revenue of $4.82 million, compared with the revenue of $4.07 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $18.5 million, an increase of 21.1% from last year. For the last five years Viveve Medical Inc had an average revenue growth rate of 138.2% a year.
The reported loss per diluted share was $1.61 for the year, compared with the loss per share of $10.16 in the previous year. The Viveve Medical Inc had an operating margin of -242.83%, compared with the operating margin of -220.63% a year before. The 10-year historical median operating margin of Viveve Medical Inc is -315.58%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Viveve Medical Inc has the cash and cash equivalents of $29.5 million, compared with $20.7 million in the previous year. The long term debt was $30.5 million, compared with $28.9 million in the previous year. Viveve Medical Inc has a financial strength rank of 2 (out of 10).
At the current stock price of $0.92, Viveve Medical Inc is traded at 55.1% discount to its historical median P/S valuation band of $2.05. The P/S ratio of the stock is 1.27, while the historical median P/S ratio is 2.80. The stock lost 77.62% during the past 12 months.
For the complete 20-year historical financial data of VIVE, click here.
